Document Detail


Diagnostic significance of FDG-PET and argyrophilic nucleolar organizer regions (AgNORs) in oral squamous cell carcinoma.
MedLine Citation:
PMID:  14693244     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Neoadjuvant chemoradiotherapy has played an important role in preserving organs and functions in patients with oral squamous cell carcinoma (SCC). To determine whether further operation after chemoradiotherapy is necessary, accurate evaluation of residual tumour cells after treatment is essential. We investigated the usefulness of regional fluorodeoxyglucose (FDG) uptake in combination with histochemical expression of AgNORs obtained from pretreatment biopsy specimens to assess residual tumours after intraarterial chemoradiotherapy. Standardized uptake value (SUV: pretreatment, pre-SUV; post-treatment, post-SUV) was calculated to determine the changes of FDG uptake in the tumour before and after chemoradiotherapy. Four out of 20 patients with oral SCCs showed residual tumour cells after treatment. Tumours with higher post-SUVs (> or =4.0) and higher AgNORs scores (> or =5.0) had significantly higher incidences of residual viable tumour cells after chemoradiotherapy (P=0.001). The results suggest that the combination of FDG-PET with AgNORs score is an excellent index for determining the optimal management of each patient following neoadjuvant chemoradiotherapy.
Authors:
Mikiko Nakamura; Kazuo Sano; Yoshimasa Kitagawa; Toshiyuki Ogasawara; Sadahiko Nishizawa; Yoshiharu Yonekura
Related Documents :
9253164 - In vitro stimulation by tumour cell media of [3h]-thymidine incorporation by mouse sple...
1286154 - Potential therapeutic targets in multistep oncogenesis.
11497274 - Tumour cell uptake g2-m accumulation and cytotoxicity of nami-a on ts/a adenocarcinoma ...
20717114 - Selective cyclooxygenase-2 silencing mediated by engineered e. coli and rna interferenc...
1714344 - The hypersensitivity of the chinese hamster ovary variant bl-10 to bleomycin killing is...
24905314 - Biological approach of anticancer activity of new benzimidazole derivatives.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Oral oncology     Volume:  40     ISSN:  1368-8375     ISO Abbreviation:  Oral Oncol.     Publication Date:  2004 Feb 
Date Detail:
Created Date:  2003-12-24     Completed Date:  2004-05-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9709118     Medline TA:  Oral Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  190-8     Citation Subset:  IM    
Affiliation:
Department of Dentistry and Oral Surgery, Fukui Medical University, Fukui 910-1193, Japan. mikikon@fmsrsa.fukui-med.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Carcinoma, Squamous Cell / diagnosis*,  radionuclide imaging,  therapy
Combined Modality Therapy
Female
Fluorodeoxyglucose F18 / diagnostic use*
Humans
Male
Middle Aged
Mouth Neoplasms / diagnosis*,  radionuclide imaging,  therapy
Neoadjuvant Therapy
Neoplasm, Residual
Nucleolus Organizer Region* / pathology
Prognosis
Radiopharmaceuticals / diagnostic use*
Silver Staining
Tomography, Emission-Computed
Chemical
Reg. No./Substance:
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Salvage surgery as the primary treatment for recurrent oral squamous cell carcinoma.
Next Document:  Okadaic acid stimulates expression of Fas receptor and Fas ligand by activation of nuclear factor ka...